Table 4 Combined response outcomes in gilteritinib-treated R/R AML patients by prior TKI status from the CHRYSALIS and ADMIRAL trials.

From: Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Response parameter, n (%)

120-mg Gilteritinib (N = 303)

 

Prior TKI (n = 48)

No Prior TKI (n = 255)

CR

7 (15)

52 (20)

CRi

13 (27)

67 (26)

CRp

5 (10)

16 (6)

PR

6 (13)

31 (12)

NR

14 (29)

75 (29)

NE

3 (6)

14 (5)

CRca

25 (52)

135 (53)

  1. Bold font indicates aggregate responses.
  2. aDefined as the sum of patients who achieved CR, CRi, and CRc.
  3. AML acute myeloid leukemia, CR complete remission, CRc composite complete remission, CRi complete remission with incomplete hematologic recovery, CRp complete remission with incomplete platelet recovery, NE not evaluable, NR no response, PR partial remission, R/R relapsed or refractory, TKI tyrosine kinase inhibitor.
Back to article page